Biogen Inc.

A long-time analyst resets his Palantir stock forecast.

Stocks rallied after an encouraging PCE inflation print, but not every company is a winner today.

Analysts' stock picks include retail, consumer, and healthcare stocks.

The healthcare sector has trailed far behind the overall stock market so far this year, creating 'opportunities.'

Morningstar assigned all five wide moat (durable competitive advantage) ratings and sees them as undervalued.

Important FDA news is coming for Eli Lilly and Biogen's Alzheimer's disease drugs, but only one of them may be worth buying now.

Stock futures higher ahead of key market tests; Week Ahead: Fed, inflation, retail sales in focus; Biogen surges as FDA panel gives final nod to Alzheimer's treatment; Oracle set for new record high ahead of Q4 earnings and Silvio Berlusconi, billionaire media mogul and former prime minister of Italy, dies at 86.

"This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline," Eli Lilly said.

As Wall Street returns for the first full trading week of 2023, here's why we're turning our attention to Goldman Sachs, Alibaba, Biogen, Macy's, Lululemon and more.

A congressional report finds the FDA's approval process for Biogen's Alzheimer's treatment was 'rife with irregularities' that included 'atypical collaboration.'

"These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently," the Alzheimer's Association said.

Stock futures nudge higher will Powell, jobs data in focus; Powell speech may challenge Fed's new rate hike outlook; Sam Bankman-Fried set for DealBook summit appearance after FTC collapse; Biogen shares jump after promising Alzheimer's treatment data and HPE shares surge after Q4 earnings beat, solid near-term outlook.

Science.org reported Sunday that a woman participating in the joint Biogen-Eisai Clarity AD trial of an experimental Alzheimer's treatment has died of a brain hemorrhage.

"While the (trial) results are not what we hoped, we are proud to have delivered a high quality, clear and comprehensive Alzheimer’s dataset to the field," Roche said.

Brain swelling and inflammation is a common side effect among plaque-clearing drugs. It may make some patients ineligible for treatment.

Biogen stock is up almost 40% on Wednesday but is barely holding above a key level. Let's look at the chart.

Biogen and Eisai announced a positive surprise for a closely-watched Alzheimer's drug candidate in a late-stage study.

A surprise move to stem soaring bond yields by the Bank of England has U.S. stocks ending higher Wednesday.

“Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease," said Biogen CEO Michel Vounatsos.

It's Fed week, which means talk will turn to rates and whether the Fed did too much or not enough. What really matters is what the market is doing. Plus COST, MP, ENVX, CRWD, AVGO, and BIIB.

The S&P and NASDAQ rally, while the Russell doesn't. Sentiment can offer clues as to what's happening. Plus PHM, BIIB, SHOP, GILD, RUN, and MTCH.

What happened Wednesday was as entertaining as it was amazing. However, early August is not the same as late July. It gets rough from here. Oh, and get ready for Apple and Amazon!

Here are two names that remain reasonably valued even as the market becomes increasingly overbought.

It’s possible the overbought reading in the Nasdaq 100 ETF is meaningless, but I don’t think so.

Here's why I'm watching this biotech and ad-tech company.

On Wednesday, there are at least five Fed appearances including the Fed Chair himself from Washington.

Here's how I'd play the SPDR S&P Biotech exchange-traded fund.

Sure, we rallied on Monday, but the indicators haven't budged. Let's look at the charts of Nasdaq and the S&P, Apple, and the biotechs.

Let's look at the new lows on Nasdaq, the bond fund, and, of course, good old Apple.

Is this a buy the dip move?

No, Mike Wilson was not wrong about corporate performance, he simply misjudged the marketplace, which is easy to do.

Let's check this drugmaker following a key FDA win.

This will obviously be a huge market. It's time for me to diversify my exposure after positive news on Biogen and Eisai's Leqembi.

Traders should operate from the long side.

I would rather worry about underperformance during a bull market than celebrate outperformance in a bear market.

Let's see how traders could react to the latest news.

If I had to be long MSFT or GOOGL going into tonight's digits, here's who I would choose.

Overnight the U.K saw some of the biggest swings to date in its bond market, as panic set in.

The retailer is struggling to combat a growing issue.

Global travel agency platform files for bankruptcy facing industry headwinds.

TikTok's future in the United States depends entirely on the incoming president's support. President-elect Trump will be pushing for investors to see his show.